Shares of Knight Therapeutics Inc. (TSE:GUD - Get Free Report) dropped 0.7% on Monday . The stock traded as low as C$6.04 and last traded at C$6.09. Approximately 82,521 shares traded hands during trading, an increase of 25% from the average daily volume of 66,027 shares. The stock had previously closed at C$6.13.
Analyst Upgrades and Downgrades
GUD has been the topic of several research analyst reports. Stifel Nicolaus boosted their target price on Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics and gave the stock a "buy" rating in a research note on Friday, May 9th. Two analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Strong Buy" and a consensus target price of C$7.15.
Read Our Latest Analysis on Knight Therapeutics
Knight Therapeutics Trading Down 1.1%
The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The company has a 50 day simple moving average of C$5.91 and a two-hundred day simple moving average of C$5.79. The firm has a market cap of C$621.06 million, a PE ratio of -20.50, a P/E/G ratio of -1,013.50 and a beta of 0.50.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Recommended Stories
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
